JP2019516733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516733A5 JP2019516733A5 JP2018560759A JP2018560759A JP2019516733A5 JP 2019516733 A5 JP2019516733 A5 JP 2019516733A5 JP 2018560759 A JP2018560759 A JP 2018560759A JP 2018560759 A JP2018560759 A JP 2018560759A JP 2019516733 A5 JP2019516733 A5 JP 2019516733A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- oxo
- pyrido
- trifluoro
- hydroxyethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 16
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 10
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 9
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 9
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims description 8
- 208000036566 Erythroleukaemia Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 208000000172 Medulloblastoma Diseases 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 8
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 8
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 8
- 229960003852 atezolizumab Drugs 0.000 claims description 8
- 229950002916 avelumab Drugs 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 229950009791 durvalumab Drugs 0.000 claims description 8
- 201000010536 head and neck cancer Diseases 0.000 claims description 8
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 8
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 229960003301 nivolumab Drugs 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 229960002621 pembrolizumab Drugs 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 201000000849 skin cancer Diseases 0.000 claims description 7
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 15
- 238000007911 parenteral administration Methods 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- TUCVAXGUCJNKBE-LIRRHRJNSA-N C(CCC)(=O)N[C@H](C(=O)N[C@@H]1C(N(C2=C(C3=C1C=CC=C3)C=CC=N2)CCO)=O)C Chemical compound C(CCC)(=O)N[C@H](C(=O)N[C@@H]1C(N(C2=C(C3=C1C=CC=C3)C=CC=N2)CCO)=O)C TUCVAXGUCJNKBE-LIRRHRJNSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| US62/339,363 | 2016-05-20 | ||
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516733A JP2019516733A (ja) | 2019-06-20 |
| JP2019516733A5 true JP2019516733A5 (OSRAM) | 2020-07-02 |
| JP7194022B2 JP7194022B2 (ja) | 2022-12-21 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560759A Active JP7194022B2 (ja) | 2016-05-20 | 2017-05-16 | Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (OSRAM) |
| EP (1) | EP3458091B1 (OSRAM) |
| JP (1) | JP7194022B2 (OSRAM) |
| KR (1) | KR102463617B1 (OSRAM) |
| CN (2) | CN109475629A (OSRAM) |
| AU (1) | AU2017268187A1 (OSRAM) |
| BR (1) | BR112018073673A2 (OSRAM) |
| CA (1) | CA3025024A1 (OSRAM) |
| ES (1) | ES2904880T3 (OSRAM) |
| IL (1) | IL263110B (OSRAM) |
| MA (1) | MA45025A (OSRAM) |
| MX (1) | MX2018013941A (OSRAM) |
| SG (1) | SG11201810268YA (OSRAM) |
| WO (1) | WO2017200969A1 (OSRAM) |
| ZA (1) | ZA201807585B (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| CA3020875A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
| RU2754452C2 (ru) | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
| ES2904880T3 (es) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 |
| WO2018071307A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| CA3080395A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| JP2021506968A (ja) * | 2017-12-18 | 2021-02-22 | デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． | 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用 |
| WO2021084441A2 (en) * | 2019-10-28 | 2021-05-06 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
| AU2021443620A1 (en) * | 2021-04-28 | 2023-10-26 | Obi Pharma, Inc. | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158355A0 (en) | 1996-12-23 | 2004-05-12 | Elan Pharm Inc | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP1117778A2 (en) | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) * | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| CA3001152A1 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| JP5385904B2 (ja) | 2007-08-14 | 2014-01-08 | イーライ リリー アンド カンパニー | γ−セクレターゼ阻害剤 |
| KR20140007979A (ko) | 2008-01-11 | 2014-01-20 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 감마-세크레타제 저해제의 용도 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011026506A1 (de) | 2009-08-26 | 2011-03-10 | Frxsh Ag | Vorrichtung und verfahren zum mischen von mischgut |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JP2013532153A (ja) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| MY193562A (en) * | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| JP6586087B2 (ja) * | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| CA2960824A1 (en) * | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| BR112017008710A8 (pt) * | 2014-10-27 | 2023-04-25 | Hutchinson Fred Cancer Res | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva |
| ES2808153T3 (es) * | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| PL3226897T3 (pl) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania |
| WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX2018000999A (es) | 2015-07-24 | 2018-11-09 | Oncotracker Inc | Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. |
| RU2754452C2 (ru) | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
| CA3020875A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
| ES2904880T3 (es) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 |
| CN109562114A (zh) | 2016-08-31 | 2019-04-02 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| WO2018071307A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CA3080395A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt unknown
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko active Active
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516733A5 (OSRAM) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2023041862A5 (OSRAM) | ||
| JP2014512356A5 (OSRAM) | ||
| JP2009539769A5 (OSRAM) | ||
| ES2717898T3 (es) | Efecto potenciador para agentes antitumorales | |
| ZA201807585B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| JP2019506403A5 (OSRAM) | ||
| JP2014509657A5 (OSRAM) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2017536408A5 (OSRAM) | ||
| JP2019517549A5 (OSRAM) | ||
| EP2501385B1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| JP2020516646A5 (OSRAM) | ||
| JP2019511529A5 (OSRAM) | ||
| JP2019534251A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| JP2021505669A5 (OSRAM) | ||
| JP2015510945A5 (OSRAM) | ||
| EP2344156B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
| RU2021126526A (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб | |
| TW201313225A (zh) | 與放射線治療關聯之包含奧瑞布林（ｏｍｂｒａｂｕｌｉｎ）及順鉑（ｃｉｓｐｌａｔｉｎ）之抗腫瘤組合 | |
| UA115803U (xx) | Спосіб лікування вертеброгенних радикулопатій | |
| UA117052U (uk) | Спосіб лікування хворих на інфаркт міокарда при супутній артеріальній гіпертензії з використанням кверцетину |